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Introduction
Neuropsychiatric manifestations are considered to be a
serious complication in childhood-onset systemic lupus
erythematosus (cSLE). The pathogenesis of neuropsychia-
tric manifestations has been attributed to autoantibody-
mediated neural dysfunction.
Objectives
To investigate the prevalence and associations of neurop-
sychiatric manifestations with antiribosomal P protein
antibodies, S100b, subunit of high molecular weight
neurofilament (NF-H), antiphospholipid [anticardiolipin
(aCL) and lupus anticoagulant (LA)], anti-dsDNA and
anti-Smith.
Methods
We included consecutive cSLE followed at the pediatric
rheumatology unit of the State University of Campinas.
Neurological manifestations were analyzed according to
the ACR classification criteria. Cognitive evaluation was
performed in all participants using Wechsler Intelligence
Scale for children (WISC-III) and Wechsler Intelligence
Scale for adults (WAIS), according to age and validated in
Portuguese. Mood disorders were determined through
Becks Depression and Anxiety Inventory in all partici-
pants. SLE patients were further assessed for clinical and
laboratory SLE manifestations, disease activity [SLE Dis-
ease Activity Index (SLEDAI)], damage [Systemic Lupus
International Collaborating Clinics/American College of
Rheumatology Damage Index (SDI)] and current drug
exposures. Antiribosomal P protein antibodies, S100b and
NF-H were tested by ELISA using commercial kits. The
levels of dsDNA antibodies were determined by indirect
immunofluorescence using Crithidiaas a substrate and
were considered positive if they were higher than 110. The
levels of precipitating antibodies to extractable nuclear
antigens (ENA), including Sm, were detected using a
standardized enzyme-linked immunosorbent assay
(ELISA) method and were considered positive if higher
than 180. The levels of IgG and IgM anticardiolipin
antibodies (aCL) were measured by ELISA. Lupus
anticoagulant (LA) activity was detected by coagulation
assays in platelet-free plasma obtained by double centrifu-
gation following the recommendations of the Scientific
and Standardization Committee of the International
Society of Thrombosis and Homeostasis subcommittee on
LA Antiphospholipid (aCL and LA), anti-dsDNA and anti-
Smith were obtained of the medical charts. Data were
compared by non-parametric tests.
Results
We included 77 cSLE patients (69 women; mean age 17.64
±4.64 years). The mean disease duration was 4.35±3.9
years . At time of study entry, 33 (42.85%) cSLE patients
had active disease (mean SLEDAI scores 3.58±3.97; range
0-14). Eighteen (23.37%) cSLE had cumulative damage
(mean SDI scores 0.35±0.67; range 1-3). We observed
neuropsychiatric manifestations in 49 (63.63%) cSLE. The
most frequent manifestations observed in our cohort were
cognitive impairment (46.93%), depression (36.73%) and
seizure (24.48%). Mean NF-H protein levels were 101.80
±89.40 pg/mL and mean serum S100b levels were 148.98
± 102.73 pg / mL in cSLE. antiP were positive in 13
(16.8%), aCL in 15 (19.5%), LA in 29 (37.7%), dsDNA in
31 (40.3%) and anti-Sm in 11 (14.3%) cSLE patients.
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We did not observe an association between the presence
of neuropsychiatric manifestations and any of the tested
autoantibodies.
Conclusion
Although frequently observed in cSLE antiribosomal
P protein antibodies, aCL and LA, anti-dsDNA and
anti-Smith, S100B and NF-H are not good biomarkers for
neuropsychiatric manifestations.
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